<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668185</url>
  </required_header>
  <id_info>
    <org_study_id>15HH2867</org_study_id>
    <nct_id>NCT02668185</nct_id>
  </id_info>
  <brief_title>Neuropeptide Treatment for Hot Flushes During the Menopause</brief_title>
  <acronym>NK3R</acronym>
  <official_title>Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational&#xD;
      product&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blinded, placebo-controlled, 2-way crossover study in 30 menopausal women with&#xD;
      untreated hot flushes treated with a neurokinin 3 receptor (NK3R) antagonist&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      To investigate whether an NK3R antagonist can reduce menopausal flushing&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      4 weeks administration of active drug and placebo in random order&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period</measure>
    <time_frame>Final week of each 4 week treatment period</time_frame>
    <description>To ensure accurate records, participants recorded their flushes in real time using either a tally chart on a piece of paper (n=34) or an application on their smartphone such as Tally Counter (Pixel Research Labs, Minneapolis-Saint Paul, MN, USA; n=3), and then collated their total number of flushes twice daily on waking to record previous overnight symptoms and before bed to record daytime symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hot Flush Severity</measure>
    <time_frame>Twice daily, morning and night for 14 weeks</time_frame>
    <description>Score on a scale - HF severity (rated as 1-nil, 2-mild, 3-moderate, 4-severe, as per Joffe 2014) recorded twice daily (day/night as described above for HF frequency). Scores are summed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hot Flush Bother</measure>
    <time_frame>twice daily (day/night) for 14 weeks</time_frame>
    <description>Score on a scale - HF bother (rated as 1-none, 2-a little, 3-moderate, 4-a lot, as per Joffe 2014) will be recorded twice daily (day/night as described above for HF frequency). The data will be analysed as detailed above for the HF frequency. Scores are summed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hot Flush Interference</measure>
    <time_frame>Daily at bedtime for 14 weeks</time_frame>
    <description>Score on a scale Menopause Specific Quality of Life (MENQOL) questionnaire 0=not bothered at all - 6=extremely bothered. 4 domains, mean calculated for set of questions in each domain. Overall score is a mean of the means. Highr scor = higher interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Conductance Monitor Data.</measure>
    <time_frame>Once per week for 48 hours over 14 weeks</time_frame>
    <description>Mean number of flushes detected during the 48 hours by the skin conductance monitoring will be compared each week when the patients receive AZD4901 versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Menopausal Flushing</condition>
  <arm_group>
    <arm_group_label>Active drug first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Washout period - 2 weeks Matched placebo orally bd - 2 weeks Monitoring period - 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Baseline period - 2 weeks Matched placebo orally bd - 2 weeks Washout period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Monitoring period - 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NK3R antagonist - AZD4901</intervention_name>
    <description>Neurokinin 3 receptor antagonist</description>
    <arm_group_label>Active drug first</arm_group_label>
    <other_name>nil others</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>nil others</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Menopausal women (≥12 months since last menstrual period or bilateral oophorectomy or&#xD;
             with a follicle stimulating hormone (FSH) level ≥20 milli-international&#xD;
             units/millilitre (mIU/mL) and an estradiol level &lt;190pmol/l in the absence of a&#xD;
             reliable menstrual marker (hysterectomy with ovarian preservation or endometrial&#xD;
             ablation)) aged 40-62 years with &gt;7 hot flushes/day some of which are reported as&#xD;
             severe or bothersome who have not been on treatment for menopausal symptoms for the&#xD;
             preceding 8 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant illness, as judged by the Investigator, within 2 weeks of first study&#xD;
             visit.&#xD;
&#xD;
          2. Volunteer has clinical, laboratory, or electrocardiogram (ECG) evidence of&#xD;
             uncontrolled hypertension (defined as systolic blood pressure of ≥ 160 mmHg and/or&#xD;
             diastolic blood pressure of ≥100 mmHg); uncontrolled diabetes; or significant&#xD;
             pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          3. Participant has a history of Gilbert's syndrome, infectious hepatitis, or other&#xD;
             significant hepatic disease (e.g. chronic hepatitis, cirrhosis, autoimmune hepatitis,&#xD;
             primary sclerosing cholangitis, non-alcoholic steatohepatitis, or hereditary liver&#xD;
             disease) in the opinion of the Investigator.&#xD;
&#xD;
          4. Participant has a history of surgery which in the opinion of the investigator could&#xD;
             cause malabsorption (e.g. gastric or small intestinal surgery or gastric bypass&#xD;
             surgery or banding), or patient has a disease that causes malabsorption.&#xD;
&#xD;
          5. Clinically significant abnormal ECG and/or abnormalities in ECG at screening as judged&#xD;
             by the Investigator.&#xD;
&#xD;
          6. A marked prolongation of QT/corrected QT (QTc) interval (e.g. repeated demonstration&#xD;
             of a QTc interval &gt; 450 ms).&#xD;
&#xD;
          7. Confirmed history of ischaemic heart disease.&#xD;
&#xD;
          8. Past (within 1 year of enrollment) or present alcohol or substance abuse&#xD;
&#xD;
          9. Has received another new chemical entity (defined as a compound which has not been&#xD;
             approved for marketing) or has participated in any other clinical study that included&#xD;
             drug treatment within at least 3 months of the first administration of AZD4901 in this&#xD;
             study. The period of exclusion begins 3 months after the final dose. (Note: patients&#xD;
             consented and screened, but not randomised in a previous study are not excluded.)&#xD;
&#xD;
         10. Participant has a history of neoplastic disease within 5 years prior to signing&#xD;
             informed consent or is currently on ongoing treatment to prevent cancer recurrence.&#xD;
&#xD;
         11. Involvement in the planning and/or conduct of the study (applies to any AstraZeneca&#xD;
             employee and their close relatives and/or staff at the study site directly involved in&#xD;
             the study, regardless of their role in accordance with their internal procedures)&#xD;
&#xD;
         12. Inability to understand or cooperate with the requirements of the study&#xD;
&#xD;
         13. Participant is legally or mentally incapacitated&#xD;
&#xD;
         14. Participant has significant psychiatric disease or treatment for psychiatric disease&#xD;
             e.g. selective serotonin re-uptake inhibitors (SSRIs) which in the opinion of the&#xD;
             Investigator may influence the results of the study.&#xD;
&#xD;
         15. Participant has abnormal screening laboratory values as per the guidelines listed&#xD;
             below or other clinically significant, unexplained laboratory abnormality according to&#xD;
             the Investigator:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt;1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt; 1.5 times ULN&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 times ULN&#xD;
&#xD;
               -  Serum creatinine &gt;2.0 times ULN&#xD;
&#xD;
         16. Clinically relevant disease and abnormalities (past or present), which in the opinion&#xD;
             of the Investigator, may either put the patient at risk to participate in this study&#xD;
             or may influence the results of the study or the patient's ability to participate in&#xD;
             the study.&#xD;
&#xD;
         17. Participant has a history of hyperthyroidism or hypothyroidism or abnormal screening&#xD;
             thyroid tests, as judged by the Investigator. Patients with hypothyroidism who are&#xD;
             stable on treatment with normal thyroid function tests may be included in the study if&#xD;
             in the opinion of the Investigator this will not influence the results of the study.&#xD;
&#xD;
         18. Participant has seizures, patients with history of seizures or with conditions that&#xD;
             increase the risk of seizures.&#xD;
&#xD;
         19. Participant has a history of hypersensitivity to more than 2 chemical classes of&#xD;
             drugs, including prescription and over-the-counter medications.&#xD;
&#xD;
         20. Participant has taken any potent or moderate CYP3A4 or CYP2C9 inhibitors, potent or&#xD;
             moderate CYP3A4 or CYP2C9 inducers, hormonal contraceptives, antiandrogenic drugs, or&#xD;
             other medications specified for the time frame&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Menopausal women (≥12 months since last menstrual period or bilateral oophorectomy or with a follicle stimulating hormone (FSH) level ≥20 milli-international units/millilitre (mIU/mL) and an estradiol level &lt;190pmol/l in the absence of a reliable menstrual marker (hysterectomy with ovarian preservation or endometrial ablation)) aged 40-62 years with &gt;7 hot flushes/day some of which are reported as severe or bothersome who have not been on treatment for menopausal symptoms for the preceding 8 weeks.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waljit S Dhillo, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College and NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIHR/Wellcome Trust Imperial CRF</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <results_first_submitted>August 12, 2019</results_first_submitted>
  <results_first_submitted_qc>April 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2021</results_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopausal flushing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flushing</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Drug First Then Placebo</title>
          <description>2 week baseline period First NK3R antagonist - AZD4901 - 40mg orally bd - for 4 weeks intervention then 2 weeks washout period then second intervention with Matched placebo orally bd for 4 weeks with 2 weeks monitoring period</description>
        </group>
        <group group_id="P2">
          <title>Placebo First Then Active Drug</title>
          <description>2 week baseline period First intervention is Placebo - 40mg bd - for 4 weeks, then 2 weeks washout period, then second intervention with NK3R antagonist - AZD4901 - 40mg orally bd - for 4 weeks with 2 weeks monitoring period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Period (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Moitoring Period (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Participants</title>
          <description>Crossover study - all participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White British</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White European</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pakistani</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Carribean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed white and black carribean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period</title>
        <description>To ensure accurate records, participants recorded their flushes in real time using either a tally chart on a piece of paper (n=34) or an application on their smartphone such as Tally Counter (Pixel Research Labs, Minneapolis-Saint Paul, MN, USA; n=3), and then collated their total number of flushes twice daily on waking to record previous overnight symptoms and before bed to record daytime symptoms.</description>
        <time_frame>Final week of each 4 week treatment period</time_frame>
        <population>Whole group intention to treat analysis irrespective of treatment assignment order, adjusted means from crossover analysis with 95% CIs: percentage change in total no. hot flush frequency during final week of 4 week treatment period with MLE4901 and placebo vs with total no. hot flush frequency during the final week of the 2 week baseline period.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks&#xD;
NK3R antagonist - AZD4901: Neurokinin 3 receptor antagonist</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - 40mg bd - for 4 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period</title>
          <description>To ensure accurate records, participants recorded their flushes in real time using either a tally chart on a piece of paper (n=34) or an application on their smartphone such as Tally Counter (Pixel Research Labs, Minneapolis-Saint Paul, MN, USA; n=3), and then collated their total number of flushes twice daily on waking to record previous overnight symptoms and before bed to record daytime symptoms.</description>
          <population>Whole group intention to treat analysis irrespective of treatment assignment order, adjusted means from crossover analysis with 95% CIs: percentage change in total no. hot flush frequency during final week of 4 week treatment period with MLE4901 and placebo vs with total no. hot flush frequency during the final week of the 2 week baseline period.</population>
          <units>hot flushes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.35" lower_limit="15.99" upper_limit="23.42"/>
                    <measurement group_id="O2" value="49.01" lower_limit="40.81" upper_limit="58.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalised linear mixed model with a Poisson error structure</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intention to treat adjusted means.</p_value_desc>
            <method>generalised linear mixed model with a Po</method>
            <method_desc>Adjusted for intention to treat</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>29.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.39</ci_lower_limit>
            <ci_upper_limit>42.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hot Flush Severity</title>
        <description>Score on a scale - HF severity (rated as 1-nil, 2-mild, 3-moderate, 4-severe, as per Joffe 2014) recorded twice daily (day/night as described above for HF frequency). Scores are summed.</description>
        <time_frame>Twice daily, morning and night for 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks&#xD;
NK3R antagonist - AZD4901: Neurokinin 3 receptor antagonist</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - 40mg bd - for 4 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hot Flush Severity</title>
          <description>Score on a scale - HF severity (rated as 1-nil, 2-mild, 3-moderate, 4-severe, as per Joffe 2014) recorded twice daily (day/night as described above for HF frequency). Scores are summed.</description>
          <units>numerical rating of severity by particip</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="2.92" upper_limit="3.66"/>
                    <measurement group_id="O2" value="5.70" lower_limit="5.09" upper_limit="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hot Flush Bother</title>
        <description>Score on a scale - HF bother (rated as 1-none, 2-a little, 3-moderate, 4-a lot, as per Joffe 2014) will be recorded twice daily (day/night as described above for HF frequency). The data will be analysed as detailed above for the HF frequency. Scores are summed.</description>
        <time_frame>twice daily (day/night) for 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks&#xD;
NK3R antagonist - AZD4901: Neurokinin 3 receptor antagonist</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - 40mg bd - for 4 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hot Flush Bother</title>
          <description>Score on a scale - HF bother (rated as 1-none, 2-a little, 3-moderate, 4-a lot, as per Joffe 2014) will be recorded twice daily (day/night as described above for HF frequency). The data will be analysed as detailed above for the HF frequency. Scores are summed.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="2.61" upper_limit="3.27"/>
                    <measurement group_id="O2" value="5.56" lower_limit="4.96" upper_limit="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hot Flush Interference</title>
        <description>Score on a scale Menopause Specific Quality of Life (MENQOL) questionnaire 0=not bothered at all - 6=extremely bothered. 4 domains, mean calculated for set of questions in each domain. Overall score is a mean of the means. Highr scor = higher interference.</description>
        <time_frame>Daily at bedtime for 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks&#xD;
NK3R antagonist - AZD4901: Neurokinin 3 receptor antagonist</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - 40mg bd - for 4 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hot Flush Interference</title>
          <description>Score on a scale Menopause Specific Quality of Life (MENQOL) questionnaire 0=not bothered at all - 6=extremely bothered. 4 domains, mean calculated for set of questions in each domain. Overall score is a mean of the means. Highr scor = higher interference.</description>
          <units>Score by participant on 'interference sc</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" lower_limit="5.76" upper_limit="10.95"/>
                    <measurement group_id="O2" value="26.48" lower_limit="20.02" upper_limit="35.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Conductance Monitor Data.</title>
        <description>Mean number of flushes detected during the 48 hours by the skin conductance monitoring will be compared each week when the patients receive AZD4901 versus placebo</description>
        <time_frame>Once per week for 48 hours over 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug</title>
            <description>NK3R antagonist - AZD4901 - 40mg bd - for 4 weeks&#xD;
NK3R antagonist - AZD4901: Neurokinin 3 receptor antagonist</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - 40mg bd - for 4 weeks&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Conductance Monitor Data.</title>
          <description>Mean number of flushes detected during the 48 hours by the skin conductance monitoring will be compared each week when the patients receive AZD4901 versus placebo</description>
          <units>Number of hot flushes detected by monito</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.22" lower_limit="13.99" upper_limit="18.8"/>
                    <measurement group_id="O2" value="26.91" lower_limit="23.16" upper_limit="31.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Drug First Then Placebo</title>
          <description>2 week baseline period First NK3R antagonist - AZD4901 - 40mg orally bd - for 4 weeks intervention then 2 weeks washout period then second intervention with Matched placebo orally bd for 4 weeks with 2 weeks monitoring period</description>
        </group>
        <group group_id="E2">
          <title>Placebo First Then Active Drug</title>
          <description>2 week baseline period First intervention is Placebo - 40mg bd - for 4 weeks, then 2 weeks washout period, then second intervention with NK3R antagonist - AZD4901 - 40mg orally bd - for 4 weeks with 2 weeks monitoring period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>transaminase elevations by treatment and CTCAE grade</sub_title>
                <description>transient transaminase rise (alanine aminotransferase [ALT] greater than aspartate aminotransferase [AST]) with a normal bilirubin following treatment with MLE4901</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Wajit Dhillo</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 7594 2489</phone>
      <email>w.dhillo@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

